{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-022077","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.394523+00:00","generated_at":"2026-06-24T01:15:06.306839+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lineage reports Q2 net loss of $6.8M ($0.04/sh); cash $72M supports through Q2 2024","bullets":["Revenue $4.6M, up $4.0M YoY, primarily from Roche collaboration licensing fee.","Net loss attributable to Lineage $6.8M ($0.04/sh) vs $4.8M ($0.03/sh) in Q2 2021.","R&D expenses $3.3M; G&A $5.3M; total operating expenses $8.6M.","Cash, equivalents, and marketable securities $72M; funds operations through Q2 2024.","OpRegen collaboration with Roche advancing; OPC1 results published in J Neurosurg; VAC2 tech transfer complete."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-022077","json":"https://secwatch.observer/filing/0001493152-22-022077.json","markdown":"https://secwatch.observer/filing/0001493152-22-022077.md","text":"https://secwatch.observer/filing/0001493152-22-022077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315222022077/0001493152-22-022077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315222022077/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:15:06.306839+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}